ACT-128800 in Psoriasis

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the efficacy, safety, and tolerability of ACT-128800 in subjects with moderate to severe plaque psoriasis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Actelion
• Treatments: Ponesimod

Criteria

Inclusion Criteria:

• Adult males and females with moderate to severe plaque psoriasis who require systemic treatment and for whom participation in a placebo-controlled study of an investigational drug is justified.

Exclusion Criteria:

• Patients with other forms of psoriasis and patients who are currently treated for autoimmune disorders other than psoriasis.

• Systemic or topical treatments for psoriasis other than emollients.

• Ongoing bacterial, viral or fungal infections.

• History or presence of malignancy.

• Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients' risk from participating in the study.